Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug ...

Performances in N.Y.C. Advertisement Supported by A pair of organ works that scholars believe were written by a teenage Johann Sebastian Bach were premiered in Leipzig this week and added to the ...

Two previously unknown pieces by the German composer have been revealed by the Bach Archive in Leipzig — just in time for the research institute's 75th anniversary ...

Two long-lost organ pieces by J.S. Bach have been performed publicly in Germany for the first time in more than three centuries. The Chaconne in D minor, BWV 1178, and the Chaconne in G minor, BWV ...

Two long-lost organ pieces written by a teenage Johann Sebastian Bach were unveiled in Germany on Monday in a discovery described as a "great moment for the world of music". The two solo organ works, ...

Previously unknown organ works by Johann Sebastian Bach have been presented and performed in Germany for the first time in 320 years. Germany's Culture Minister Wolfram Weimer called the discovery of ...

The Denver Broncos won one of the most exciting games in recent NFL memory in Week 7, overcoming an 18-point deficit to defeat the New York Giants 33-32. The Broncos scored all 33 points in the fourth ...

"Broncos’ 33 fourth-quarter points were the most points in the fourth quarter by any team that had been shut out in the first three quarters in NFL history," Schefter posted on X. In addition to that, ...

The New York Giants' Week 7 loss to the Denver Broncos was historic. The Giants had a 19-0 lead over the Broncos going into the fourth quarter of Sunday's game and looked set to cruise to victory.

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant ...

DENVER--(BUSINESS WIRE)--Voyager Technologies, Inc. (NYSE: VOYG), the majority holder of Starlab Space LLC, announced Vivace Corporation has been selected to manufacture the primary structure for ...